Seattle Genetics (SGEN) Beats By 7c
More News related to SGEN
- Seattle Genetics to Present at the J.P. Morgan Healthcare Conference
- Seattle Genetics Announces Interim Safety Analysis Supports Continuation of Lintuzumab Phase IIb Clinical Trial
- Seattle Genetics (SGEN) Reports Data from Phase I Trial of SGN-35
- Seattle Genetics Reports Durable Objective Responses with SGN-35 in Lymphoma
- Seattle Genetics Reports Objective Responses with Dacetuzumab in Phase II Non-Hodgkin Lymphoma Trial
More News related to Earnings
- ARGUS Downgrades Smith International (SII) to Hold
- Cantor Fitzgerald Downgrades Audiocodes (AUDC) to Hold After Negative 4Q Preannouncement
- MDB Capital Downgrades Ener1 (HEV) to Sell, Suspends Earnings Model and Valuation on Stock No Longer Justified
- DA Davidson Downgrades Ambassadors Group (EPAX) to Neutral
- SunTrust Downgrades Ruby Tuesday, Inc. (RT) to Neutral
Seattle Genetics (Nasdaq: SGEN) reports a Q2 loss of $0.20, 7 cents better than the analyst estimate of ($0.27). Revenues for the quarter were $10 million, versus the consensus of $7.63 million.
Seattle Genetics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease.
Take a look at EasyStockAlerts.com
Related Categories
EarningsStocks Mentioned
+0.15Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
